Influx Health.

How has been the historical performance of Influx Health.?

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.

Is Influx Health. overvalued or undervalued?

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

Why is Influx Healthtech Ltd falling/rising?

As of 09-Feb, Influx Healthtech Ltd's stock price is at 232.20, reflecting a 3.13% increase. The stock has outperformed the Sensex over various time frames, showing strong performance despite a decline in investor participation.

As of 09-Feb, Influx Healthtech Ltd's stock price is rising, currently at 232.20, reflecting a change of 7.05 or 3.13% increase. This upward movement can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 8.73% compared to the Sensex's 3.10%. Additionally, the stock has shown positive performance over the past month with a 3.36% increase, while the Sensex only rose by 0.72%. Year-to-date, Influx Healthtech has also performed well, with a 2.70% increase, contrasting with a decline of 1.00% in the Sensex.<BR><BR>Moreover, today's performance indicates that Influx Healthtech has outperformed its sector by 1.55%. The stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is typically a bullish sign. However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 6.78% against the 5-day average. Despite this, the stock remains liquid enough for trading, which supports its current price rise. Overall, the combination of strong recent performance relative to benchmarks and moving averages contributes to the stock's upward trajectory.

Which are the latest news on Influx Health.?